Office address: 10 East 53rd Street, 31st Floor, New York, NY 10022
Website: www.altariscap.com
Year established: 2003
Company type: venture capital and private equity principals
Employees: 40+
Expertise: healthcare, private equity, pharmaceuticals, medical devices, life sciences, diagnostics, healthcare services, biotechnology, digital health, health IT, contract manufacturing, healthcare infrastructure, medical technology, therapeutic products, bioprocessing
Parent company: N/A
Key people: George Aitken-Davies and Daniel Tully (co-founders), Aaron Bell and Lana Dweik (department heads), Charles Mullens (CFO and COO), Nicholas Fulco, Garikai Nyaruwata, Jim O’Brien, and Rafael Torres (managing directors)
Financing status: N/A
Altaris is a New York-based investment firm managing $10 billion in assets, with 7,500 employees across its portfolio companies. The company focuses on healthcare, investing in institutions that aim to improve patient access and outcomes. The firm has made over 50 platform investments, completed more than 100 acquisitions, and formed more than 25 carve-outs and corporate partnerships.
Altaris was founded in 2003 by Daniel Tully, George Aitken-Davies, and Michael Kluger to invest in mid-market life sciences and healthcare companies. The firm acquired Kindeva, a contract development and manufacturing organization, followed by Meridian, a former branch of Pfizer. The company’s healthcare and medical technology portfolio expanded after they merged Kindeva and Meridian.
Altaris also acquired Padagis, a pharmaceutical firm focused on self-care, and later partnered with Michelin to secure a 51% stake in biomaterials provider Solesis. The firm later added Veranova, a specialist API manufacturer, through a carve-out.
The company has developed through organic and inorganic growth, executing various acquisitions to drive market expansion across North America and Europe.
Altaris helps improve healthcare institutions that drive efficiency and innovation within the healthcare system. Their offerings cover the following sectors:
Altaris takes a research-driven approach to identifying investment opportunities aligned with healthcare's ongoing evolution. They collaborate closely with portfolio companies to create sustainable business plans and long-term value.
Altaris fosters a values-driven culture that prioritizes collaboration and sustainable growth. The company works closely with its partners to create ambitious business plans that support long-term success. Their culture is built on key principles that guide both their internal team and external relationships, which include:
The firm is dedicated to responsible investment, ensuring they act as good stewards of their partners' capital and the companies they oversee. They aim to be a trusted partner, ethical employer, and proactive contributor to healthcare innovation. Altaris’ commitment to environmental, social, and governance (ESG) practices shapes their business operations and long-term strategy, focusing on key areas:
Altaris takes an active role as shareholders and board members to ensure their companies have the resources, talent, and capital needed for success. Many of their portfolio companies focus on strategic acquisitions to expand their market presence and drive growth. This hands-on approach helps businesses scale effectively and reach their full potential.
George Aitken-Davies serves as a managing director and co-founder of the company, overseeing the firm's operations and serving as co-chair of the investment committee. Before this, he worked at Merrill Lynch in both New York and London, specializing in healthcare investment banking and private equity. He earned a master’s degree in biochemistry from the University of Oxford in the UK and completed his dissertation research at the Università di Padova in Italy.
Daniel Tully, also serving as a managing director and co-founder of Altaris, shares responsibility for managing the firm and co-chairs the investment committee. Prior to Altaris, he held many leadership positions at Merrill Lynch, including global head of healthcare equity capital markets. He earned a degree in economics from the University of Pennsylvania and serves as vice chair at the Hospital for Special Surgery in New York.
The leadership team at Altaris is composed of experienced professionals who drive the firm’s strategic initiatives and operations across various sectors:
Altaris is set to broaden its impact in the biotech field through its acquisition of Minaris Regenerative Medicine, a leader in cell therapy manufacturing. This move positions Altaris to enhance its expertise in cell and gene therapy, building on Minaris' established infrastructure and knowledge. The company aims to advance cell therapy development and support new medical breakthroughs around the world.
The firm recently acquired Sharecare, Inc., a digital health platform that reaches millions of people and thousands of healthcare providers. This deal helps the company strengthen its focus on healthcare technology by offering personalized tools to improve health outcomes. Taking Sharecare private allows Altaris to streamline operations and drive further growth in the company’s digital health services.
